Amarin Corp. Plc\Uk

AMRN

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000897448

E

weakest fifth of 370 graded peers in healthcare

rank 311 of 370; percentile 84.0; sampling error 2.5 points; lower is stronger

A B C D E

E, the bear



Scoreboard

Profitability	D percentile 69.9
Solvency	B/C percentile 41.5
Growth and financing	D/E percentile 77.5
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $670.8M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet not computable: dilution
Inputs computable	8 of 14
Graded from	filings received through Mar 2, 2026 239 days before the rescan; latest periodic filing 10-Q received Jul 29, 2026
Last close	$12.10 2026-10-26; market equity $5.1B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 2, 2026

- Government Regulation - Pharmaceutical Pricing and Reimbursement for further details. In many countries outside the U.S., government-sponsored healthcare systems are the primary payors for drugs. With increasing budgetary constraints and differing views on or challenges in valuing medicines, governments and payors in many countries are applying a variety of measures to exert downward price pressure. These measures can include mandatory price controls, price referencing, therapeutic-reference pricing, increases in mandates, incentives for generic substitution and biosimilar usage and government-mandated price cuts.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 69.9						
Gross profitability	18.0%	32.3%		66.3	369	2025-12-31
Return on invested capital	not computable	9.3%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(6.7%)	(6.6%)	55.1	805	2025-12-31
Gross margin stability, five years	14.3 pts	2.8 pts	88.4	242	2025-12-31
Solvency, sleeve percentile 41.5					
Twelve-month failure probability	0.04%	0.07%	25.6	247	2026-06-30
Altman Z double-prime	(2.07)	(0.33)	45.3	751	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	3.34x	2.94x	53.4	832	2025-12-31
Growth and financing, sleeve percentile 77.5					
Revenue growth, three-year compound	(16.7%)	10.1%	88.1	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	(8.9%)	2.1%	67.0	697	2025-12-31
Net share issuance, one year	not computable	2.5%			
raw and split-adjusted prices do not align at 2013-02-20					

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 594,886,000 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
306	SkinHealth Systems Inc. (SKIN)	82.7	E	
307	Karyopharm Therapeutics Inc. (KPTI)	82.9	E	dilution, distress, fortress balance sheet
308	Pyxis Oncology, Inc. (PYXS)	83.2	E	short runway, distress
309	Opko Health, Inc. (OPK)	83.5	E	fortress balance sheet
310	Novavax Inc. (NVAX)	83.7	E	
311	Amarin Corp. Plc\Uk (AMRN)	84.0	E	fortress balance sheet
312	Kalaris Therapeutics, Inc. (KLRS)	84.3	E	dilution
313	Journey Medical Corp. (DERM)	84.6	E	
314	Amgen Inc. (AMGN)	84.8	E	
315	Organon & Co. (OGN)	85.1	E	
316	Sonoma Pharmaceuticals, Inc. (SNOA)	85.4	E	dilution, fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-26 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(15.3%)	7.7%	35
Distance from 52-week high	(38.7%)	(31.2%)	38
EBIT to enterprise value	(1.0%)	(1.5%)	51
Free cash flow yield	(0.4%)	(1.0%)	52
Book value to price	0.09	0.28	24
Sales to price	0.04	0.30	15
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.38)	(0.14)	35

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$143.6M
Operating cash flow, four quarters	$15.6M
Months of runway	not finite
Days since last periodic filing	90 (10-Q received Jul 29, 2026)
Median daily dollar volume, 63 sessions	$729,829

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$120.9M	2025-12-31	2026-03-02	10-K	26-085818
2	assets	us-gaap:Assets	$670.8M	2025-12-31	2026-03-02	10-K	26-085818
3	operating income	us-gaap:OperatingIncomeLoss	-$24.3M	2019-12-31	2022-03-01	10-K	22-002401
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$22.5M	2019-12-31	2022-03-01	10-K	22-002401
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$164,000	2019-12-31	2022-03-01	10-K	22-002401
6	total debt	us-gaap:LongTermDebt	$49.7M	2019-12-31	2021-02-25	10-K	21-008382
7	book equity	us-gaap:StockholdersEquity	$608.3M	2019-12-31	2023-03-01	10-K	23-005336
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$644.6M	2019-12-31	2021-02-25	10-K	21-008382
9	total debt	us-gaap:LongTermDebt	$79.7M	2018-12-31	2020-02-25	10-K	20-006390
10	book equity	us-gaap:StockholdersEquity	$152.3M	2018-12-31	2022-03-01	10-K	22-002401
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$249.2M	2018-12-31	2020-02-25	10-K	20-006390
12	net income	us-gaap:NetIncomeLoss	-$38.8M	2025-12-31	2026-03-02	10-K	26-085818
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$6.7M	2025-12-31	2026-03-02	10-K	26-085818
14	assets	us-gaap:Assets	$685.3M	2024-12-31	2026-03-02	10-K	26-085818
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$213.6M	2025-12-31	2026-03-02	10-K	26-085818
16	gross profit	us-gaap:GrossProfit	$81.4M	2024-12-31	2026-03-02	10-K	26-085818
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$228.6M	2024-12-31	2026-03-02	10-K	26-085818
18	gross profit	us-gaap:GrossProfit	$165.5M	2023-12-31	2026-03-02	10-K	26-085818

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$306.9M	2023-12-31	2026-03-02	10-K	26-085818
20	gross profit	us-gaap:GrossProfit	$242.5M	2022-12-31	2025-03-12	10-K	25-037620
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$369.2M	2022-12-31	2025-03-12	10-K	25-037620
22	gross profit	us-gaap:GrossProfit	$461.9M	2021-12-31	2024-02-29	10-K	24-022636
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$583.2M	2021-12-31	2024-02-29	10-K	24-022636
24	current assets	us-gaap:AssetsCurrent	$649.9M	2025-12-31	2026-03-02	10-K	26-085818
25	current liabilities	us-gaap:LiabilitiesCurrent	$194.5M	2025-12-31	2026-03-02	10-K	26-085818
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.7B	2025-12-31	2026-03-02	10-K	26-085818
27	operating income	us-gaap:OperatingIncomeLoss	-$50.2M	2025-12-31	2026-03-02	10-K	26-085818
28	book equity	us-gaap:StockholdersEquity	$459.3M	2025-12-31	2026-03-02	10-K	26-085818
29	liabilities	us-gaap:Liabilities	$211.5M	2025-12-31	2026-03-02	10-K	26-085818
30	depreciation amortization	us-gaap:Depreciation	$200,000	2019-12-31	2022-03-01	10-K	22-002401
31	interest expense	us-gaap:InterestExpense	$7,000	2025-12-31	2026-03-02	10-K	26-085818
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$21.7M	2020-12-31	2023-03-01	10-K	23-005336
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$252,000	2020-12-31	2021-02-25	10-K	21-008382
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$9.4M	2019-12-31	2022-03-01	10-K	22-002401
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.5M	2019-12-31	2021-02-25	10-K	21-008382
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$94.7M	2018-12-31	2021-02-25	10-K	21-008382
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$58,000	2018-12-31	2021-02-25	10-K	21-008382
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivitiesC...	-$32.8M	2017-12-31	2018-02-27	10-K	18-003389
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$12,000	2017-12-31	2020-02-25	10-K	20-006390
40	depreciation amortization	us-gaap:Depreciation	$600,000	2020-12-31	2023-03-01	10-K	23-005336
41	operating income	us-gaap:OperatingIncomeLoss	-$19.7M	2020-12-31	2023-03-01	10-K	23-005336
42	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$17.3M	2020-12-31	2023-03-01	10-K	23-005336
43	income tax	us-gaap:IncomeTaxExpenseBenefit	$745,000	2020-12-31	2023-03-01	10-K	23-005336
44	current assets	us-gaap:AssetsCurrent	$879.2M	2020-12-31	2022-03-01	10-K	22-002401
45	current liabilities	us-gaap:LiabilitiesCurrent	$307.4M	2020-12-31	2022-03-01	10-K	22-002401
46	current assets	us-gaap:AssetsCurrent	$855.0M	2019-12-31	2021-02-25	10-K	21-008382
47	current liabilities	us-gaap:LiabilitiesCurrent	$242.2M	2019-12-31	2021-02-25	10-K	21-008382
48	assets	us-gaap:Assets	$831.7M	2023-12-31	2025-03-12	10-K	25-037620
49	assets	us-gaap:Assets	$886.2M	2022-12-31	2024-02-29	10-K	24-022636
50	shares outstanding	dei:EntityCommonStockSharesOutstanding	380,694	2013-02-20	2013-02-28	10-K	13-084191
51	shares outstanding	dei:EntityCommonStockSharesOutstanding	136,059,695	2012-02-23	2012-02-29	10-K	12-089181

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.